Evaluating immunotherapy for liver cancer in Chinese patients
Official title: A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
Run by The First Affiliated Hospital with Nanjing Medical University · NCT06241326 · Data updated 2026-11-12
This study is testing how well immunotherapy treatments work for Chinese patients with liver cancer to see if they are safe and effective in real-life situations.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 11000 (estimated) |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | April 10, 2024 |
| Trial ID | NCT06241326 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old diagnosed with hepatocellular carcinoma who may benefit from immunotherapy-based combination treatments.
✕Probably not a fit
Patients who are pregnant, lactating, or have other conditions deemed unsuitable by investigators may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on Chinese patients diagnosed with hepatocellular carcinoma (HCC) to assess the safety and efficacy of immunotherapy-based combination therapies in real-world clinical settings. The study aims to gather and analyze data regarding the clinical characteristics, treatment modalities, and outcomes of HCC patients receiving these treatments. By understanding the effectiveness of these regimens, the research seeks to inform future treatment patterns for liver cancer in this population.
Why it matters
Potential benefit: If successful, this study could provide insights into effective immunotherapy treatments for liver cancer, potentially improving patient outcomes.
How similar studies have gone: Other studies have shown promise in using immunotherapy for liver cancer, indicating that this approach has potential based on previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study. Exclusion Criteria: 1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.
Where it's running
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Xuehao Wang, professor
- Email: mxrlwx19911990@163.com
- Phone: 86-025-68303211
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases
This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.
-
Evaluating treatment effectiveness for liver cancer
This study is testing a new way to choose the best treatment for advanced liver cancer by looking at patient data and specific markers to see if it can improve outcomes.
-
Combining camrelizumab and apatinib with TACE for liver cancer treatment
This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.
-
Immunotherapy using GPC3-targeted CAR-T cells for liver cancer
This study is testing a new treatment using specially modified immune cells to see if they can help people with advanced liver cancer that has a specific protein called GPC3.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.